Anlon Healthcare Ltd
Anlon Healthcare Ltd Q1 FY27 Results & Concall Highlights: Capex ₹130 Cr
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: order book.
The short version
FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2. PAT margin expected for FY27 and FY28 is around 12-13%, considered conservative due to potential expansion delays.
From Anlon Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2.
- Current optimal capacity utilization is around 65-70%, with peak revenue potential from existing assets at ₹350-400 crore.
- Expansion underway at Anlon with a ₹130 crore CAPEX; capacity expected to increase by 1200 metric tonnes (from 400 to approx. 1600 metric tonnes).
- New capacity at Anlon expected to commission by Q1 FY28, aiming to drive FY28 revenue to approximately ₹700 crore.
- For FY27-28, standalone Anlon sales expected to remain around ₹180 crore, as it is operating near peak capacity.
- Growth also supported by subsidiaries Apiqo and BizoƟc, both profitable with increasing capacities and business opportunities.
- New product launches planned in peptides and pain management (cosmetic peptides and ointments) with production starting by FY28.
- CDMO projects progressing, with commercial supply expected from Q3 FY27 and FY28.
- Overall, the company is cautiously optimistic, maintaining conservative PAT margins of 12-13% for FY27-28 amid expansion-related uncertainties.
Profitability & Margins
See what Anlon Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX for expansion is around ₹130 crore focused on Anlon's standalone capacity expansion.
- The expansion will increase Anlon's capacity by approximately 1,200 metric tons (from current 400 to 1,600 metric tons).
- Construction and statutory approvals are underway, with expected commissioning by Q1 FY28 (subject to regulatory timelines).
- Debt financing of around ₹70 crore is planned for this CAPEX, with the remainder funded internally.
- Anlon Biologics subsidiary is being established for peptides and biologics manufacturing, with operations expected to start generating revenue by FY28 Q4.
- Anlon Medicare, focusing on surgical implants for trauma and orthopedic applications, is expected to generate revenue from FY28 Q2.
- Growth driven by these expansions anticipates increasing revenue potential to about ₹700 crore by FY28.
- The company is exploring further inorganic growth opportunities aligned with its strategic goals but currently focusing on consolidation of recent acquisitions.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anlon Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a specific current or expected order book value for Anlon Healthcare Limited.
- It is indicated that the company has long-term relationships with 10 to 15 key B2B customers.
- Pricing and payments are based on these long-term contracts, with payment terms generally around 90 days but actual receipts sometimes extending to 130-135 days.
- The company is focusing on strict payment terms and not working with customers who delay payments to improve receivables.
- Expansion plans and capacity increases indicate healthy future demand: new capacities expected to start contributing to revenue by Q1 FY28.
- For Q1 FY27, acquisitions Apiqo and BizoƟc contributed revenues (~45 CR and 12 CR respectively), indicating ongoing business activity.
- Exact pending orders or order book figures as of 30th July or current date were not provided but can be obtained on request from the finance team (contact Parth suggested).
Anlon Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹36 Cr, net profit ₹5 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anlon Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Anlon Healthcare Ltd Q1 FY27 results?
FY27 revenue guidance maintained at ₹380 to ₹400 crore, with H1 expected slightly lower than H2. PAT margin expected for FY27 and FY28 is around 12-13%, considered conservative due to potential expansion delays.
What is Anlon Healthcare Ltd share price analysis?
Anlon Healthcare Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 24.4 with a market cap of ₹770 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anlon Healthcare Ltd planning capital expenditure?
Current CAPEX for expansion is around ₹130 crore focused on Anlon's standalone capacity expansion.
Keep Anlon Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.